Profitability Metrics

Gross Margin
100.00%
Operating Margin
136.53%
Net Margin
135.80%

Efficiency Metrics

Revenue per Expense Ratio
-6,360,710.0
R&D as % of Revenue
0.00%

Earnings Quality

EBITDA Margin
136.53%
Income Tax Rate
0.00%
EPS
-0.1000000000

Balance Sheet Analysis

Current Ratio
0.14
Cash Ratio
1.65
Working Capital
$-10.62M
Debt to Equity
0.01
Debt to Assets
0.68%
Equity Ratio
98.09%

Cash Flow Analysis

Operating Cash Flow Ratio
-668.41%
Free Cash Flow Ratio
-668.41%
CapEx to Revenue
0.00%
Dividends Paid
$53.56M
Stock Buybacks
$30.52M
Total Shareholder Returns
$84.08M
Cash Position Change
-71.46%

Key Takeaways (2023 FY)

  • Revenue declined by 104.53653220341%, indicating potential market challenges
  • Increased dividend payments by 14.53%

Detailed Growth Metrics

Core Performance

Revenue
-104.54%
Net Income
-103.11%
EPS
-103.15%
Operating Income
-221.64%

Operational Efficiency

R&D Expenses
-100.00%
SG&A Expenses
20.97%
Operating Cash Flow
-22.90%
Free Cash Flow
-22.90%

Balance Sheet Health

Assets
-8.42%
Debt
5,128.47%
Book Value per Share
-5.95%
Inventory
0.00%

Shareholder Returns

Dividends per Share
14.53%
Shares Outstanding
-3.61%

Long Term Trends

3Y Revenue/Share
28.64%
5Y Revenue/Share
95.24%
3Y Dividend/Share
17.98%
5Y Dividend/Share
1.19%